Prevalence of anti-tick-borne encephalitis virus (TBEV) antibodies in Swiss blood donors in 2014-2015.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
26
04
2022
accepted:
22
07
2022
pubmed:
16
8
2022
medline:
21
3
2023
entrez:
15
8
2022
Statut:
ppublish
Résumé
Disease morbidity of tick-borne encephalitis (TBE) has been increasing over the last decades. Since the 1990s, however, no extensive seroprevalence studies on TBE in humans have been performed in Switzerland. Here we assessed the prevalence of anti-TBE virus (TBEV) antibodies among different groups of the Swiss blood donor population. The study was carried out from July 2014 to January 2015. Blood donors participating in the study (n=9,328) were asked to fill in a questionnaire relating to vaccination against or infection with different flaviviruses, and blood samples were collected. All samples were screened for the presence of anti-TBEV IgG antibodies using ELISA testing. Seropositivity rates in different groups of blood donors were compared using Chi square tests with Bonferroni correction. In 2014 and 2015, 24.6% of healthy Swiss blood donors indicated vaccination against TBE. Among vaccinated blood donors, antibody prevalence was significantly higher in younger (<40y: 85.3%) than older individuals (≥40 to <55y: 80.0%, ≥55y: 76.7%; p=0.005). In non-vaccinated individuals, antibody prevalence was significantly higher in younger (<40y: 10.0%) than older (≥40 to <55y: 4.0%, ≥55y: 3.9%; p<0.005), male (6.8%) than female (3.7%, p<0.0001), and blood donors from endemic (7.0%) than border (6.2%) or non-endemic regions (4.2%, p<0.001). Possible asymptomatic infection, as defined by positive IgG ELISA results in blood donors indicating no vaccination against TBEV, was found in 5.6%. Our data importantly complement the knowledge on TBEV vaccination rates and estimate the frequency of subclinical TBE in Switzerland.
Sections du résumé
BACKGROUND
Disease morbidity of tick-borne encephalitis (TBE) has been increasing over the last decades. Since the 1990s, however, no extensive seroprevalence studies on TBE in humans have been performed in Switzerland. Here we assessed the prevalence of anti-TBE virus (TBEV) antibodies among different groups of the Swiss blood donor population.
MATERIALS AND METHODS
The study was carried out from July 2014 to January 2015. Blood donors participating in the study (n=9,328) were asked to fill in a questionnaire relating to vaccination against or infection with different flaviviruses, and blood samples were collected. All samples were screened for the presence of anti-TBEV IgG antibodies using ELISA testing. Seropositivity rates in different groups of blood donors were compared using Chi square tests with Bonferroni correction.
RESULTS
In 2014 and 2015, 24.6% of healthy Swiss blood donors indicated vaccination against TBE. Among vaccinated blood donors, antibody prevalence was significantly higher in younger (<40y: 85.3%) than older individuals (≥40 to <55y: 80.0%, ≥55y: 76.7%; p=0.005). In non-vaccinated individuals, antibody prevalence was significantly higher in younger (<40y: 10.0%) than older (≥40 to <55y: 4.0%, ≥55y: 3.9%; p<0.005), male (6.8%) than female (3.7%, p<0.0001), and blood donors from endemic (7.0%) than border (6.2%) or non-endemic regions (4.2%, p<0.001). Possible asymptomatic infection, as defined by positive IgG ELISA results in blood donors indicating no vaccination against TBEV, was found in 5.6%.
DISCUSSION
Our data importantly complement the knowledge on TBEV vaccination rates and estimate the frequency of subclinical TBE in Switzerland.
Identifiants
pubmed: 35969138
pii: 2022.0099-22
doi: 10.2450/2022.0099-22
pmc: PMC10072989
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-109Références
Wien Med Wochenschr. 2010 May;160(9-10):252-5
pubmed: 20632154
Transfusion. 2009 Aug;49 Suppl 2:1S-29S
pubmed: 19686562
Euro Surveill. 2018 Nov;23(45):
pubmed: 30424829
Brain. 1999 Nov;122 ( Pt 11):2067-78
pubmed: 10545392
Euro Surveill. 2010 Jul 08;15(27):24-31
pubmed: 20630144
Vaccine. 2017 Jun 16;35(28):3607-3613
pubmed: 28545923
J Intern Med. 1989 Mar;225(3):173-7
pubmed: 2703799
PLoS One. 2013 Apr 24;8(4):e62390
pubmed: 23638062
Curr Opin Physiol. 2018 Dec;6:16-20
pubmed: 30320243
Clin Infect Dis. 2002 Sep 15;35(6):650-8
pubmed: 12203160
Int J Med Microbiol. 2004 Apr;293 Suppl 37:63-8
pubmed: 15146986
Vet Parasitol. 2010 Feb 10;167(2-4):92-4
pubmed: 19833440
Scand J Infect Dis. 1996;28(3):217-24
pubmed: 8863349
Transfusion. 2000 Mar;40(3):274-84
pubmed: 10738026
Antiviral Res. 2019 Apr;164:23-51
pubmed: 30710567
Transfus Med Rev. 2015 Jul;29(3):153-61
pubmed: 25841631
J Neurol. 1997 Apr;244(4):230-8
pubmed: 9112591
Infect Dis (Lond). 2021 Jan;53(1):44-51
pubmed: 32924695
Hum Vaccin. 2009 Aug;5(8):551-6
pubmed: 19430202
Schweiz Rundsch Med Prax. 1984 May 8;73(19):601-12
pubmed: 6729325
Pathog Dis. 2015 Mar;73(2):1-3
pubmed: 25722483
Vaccine. 2020 Nov 17;38(49):7825-7833
pubmed: 33164805
Rev Med Virol. 2008 Mar-Apr;18(2):81-95
pubmed: 18183571